China

Oxford Vacmedix wins 1st prize in 2024 Talent, Innovation and Entrepreurship Competition

Oxford Vacmedix has won the 1st prize in the China Overseas Talents Competition (UK Division)   The UK section of the competition was held in London on 14th June 2024 and Oxford Vacmedix won 1st prize from a strong field of 25 competitors. The international judges were impressed by the company’s groundbreaking ROP (Recombinant Overlapping Peptide) technology and its applications to develop therapeutic vaccines to treat cancer. OVM’s lead cancer vaccine, OVM-200, is in Phase 1 cl...
Read More

Licensing deal with Dx&Vx for OVM-200 in South Korea and China

Ongoing discussions at an advanced stage with leading shareholder DxVx, to license OVM-200 for South Korea and for China. Oxford, UK – 28th November 2023 Press Release – Licensing deal with Dx&Vx for OVM-200 in South Korea and China Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today ongoing licensing discussions with its largest shareholder DxVx for lead cancer vaccine OVM-200. If concluded the licensing deal will grant DxVx...
Read More
en_GBEnglish